Testagen TDS Testosterone 5% HypoSpray not checked
Transdermal Delivery Solutions Corp
FollowEvery change as it happens, and a Monday email
Trials
10 active
13 in total · 11 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.”In the company’s words, NCT01894308 on ClinicalTrials.gov
- Tested for
- Hypogonadotropism (2 trials)
- Main trialPhase 2
- “This study will assess the potential of Testagen® TDS-Testosterone to enable transfer of Testosterone to females coming in contact with skin to which Testagen® TDS-Testosterone has been applied and the potential of product to raise serum androgen levels in those women.”In the company’s words, NCT02733133 on ClinicalTrials.gov
- Other names
- Testosterone
Other drugs for Hypogonadotropism
- SetmelanotideRhythm · Phase 3
- Testosterone cypionateAmneal Pharmaceuticals, LLC · Phase 3
- XYOSTEDHalozyme Therapeutics · Phase 3
- Recombinant human follicle-stimulating hormone-CTP Fusion proteinChangchun GeneScience Pharmaceutical Co., Ltd. · Phase 3
- RM-718Rhythm · Phase 1/2
- BivamelagonRhythm · Phase 2
Coming up2
- Oct 2027Phase 2 trial completes · ClinicalTrials.gov
- Oct 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials13
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Oct 2027 | Product Transference Study of Testagen™ TDS®-Testosterone | |
| Phase 2Not yet recruiting | Oct 2027 | A Dose Ranging Study to Examine TDS-Testosterone 5% | |
| Phase 1Ended | not given | Comparative Bioavailability and Bioequivalence of Testosterone Transdermal Gel Versus Testogel® Dosiergel 16.2 mg/g gel: A Single-Dose, Open-Label, Randomized, Full Replicate, Four-Period Crossover Study in Healthy Female Subjects Under Fasting Conditions. | |
| Phase 4Authorised | not given | Klinefelter syndrome – the effect of Testosterone treatment In PubertY A randomized, double-blind placebo-controlled intervention study ‘The TiPY study’ | |
| Phase 4Not authorised | not given | Transdermal testosterone pretreatment in poor responders with androgen receptor polymorphism undergoing ICSI: A Randomized Clinical Investigation. | |
| Phase 3Authorised | not given | Transdermal testosterone pretreatment in poor responders with androgen receptor polymorphism undergoing ICSI: A Randomized Clinical Investigation. | |
| Phase 3Ended | not given | Impact of peri-operative tEstosterone levels oN Functional and oncological Outcomes following RadiCal prostatEctomy (ENFORCE) | |
| Phase 3Authorised | not given | TRANSADO - Evaluation of the effectiveness of hormonal treatment in adolescents suffering from gender dysphoria | |
| Phase 2Authorised | not given | Testosterone Replacement Therapy in Women with Turner Syndrome – Endocrine, Cardiovascular, Physiological, Neurocognitive and Genomic effects | |
| Phase 2Authorised | not given | Prevention of Sexual Offending with Cognitive Behavioral Therapy Alone Versus Therapy Combined with Testosterone Suppression – the PREVENT-MED randomized clinical trial | |
| Phase 2Authorised | not given | TestICUs : Effects of early testosterone gel administration on physical performance in the critically ill: a randomised double blind clinical trial. | |
| Phase 2Authorised | not given | Darolutamide with Bipolar Androgen Therapy (BAT) for Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) – the DaroBAT Trial | |
| Phase 2Authorised | not given | COMPASS - COpenhagen MenoPAuSe Study |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026